Infarct evolution in a large animal model of middle cerebral artery occlusion by Shazeeb, Mohammed Salman et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/124411                                                        
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
Title: 
Infarct Evolution in a Large Animal Model of Middle Cerebral Artery Occlusion 
Authors: 
*Mohammed Salman Shazeeb1,2 (Corresponding author) 
*Robert M. King1,3 
Olivia W. Brooks1,4 
Ajit S. Puri1 
Nils Henninger5,6 
Johannes Boltze7 
Matthew J. Gounis1,2  
 
1New England Center for Stroke Research, Department of Radiology 
University of Massachusetts Medical School, Worcester, MA, 01655, USA. 
 
2Image Processing and Analysis Core, Department of Radiology 
University of Massachusetts Medical School, Worcester, MA, 01655, USA. 
 
3Department of Biomedical Engineering 
Worcester Polytechnic Institute, Worcester, MA, 01609, USA. 
 
4St. George’s University School of Medicine, Grenada, West Indies 
 
Departments of 5Neurology and 6Psychiatry 
University of Massachusetts Medical School, Worcester, MA, 01655, USA. 
 
7University of Warwick, School of Life Sciences, Coventry, CV4 7AL, United Kingdom 
 
*These authors contributed equally to this work 
 
Corresponding address: 
Mohammed Salman Shazeeb, Ph.D. 
Department of Radiology 
Division of Biomedical Imaging and Bioengineering 
University of Massachusetts Medical School 
55 Lake Avenue North, S7-410, Worcester, MA 01655, USA    
E-mail: Mohammed.Shazeeb@umassmed.edu 
Phone: 508-856-4255 
Fax: 508-856-6363 
Manuscript_revised_clean Click here to
access/download;Manuscript;Manuscript_revised_clean.docx
 Sources of funding: Dr. Henninger is supported by K08NS091499 from the National 
Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health 
(NIH). The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the NIH. Dr. Gounis has received research support from the 
NIH, the United States – Israel Binational Science Foundation, Anaconda, Cerenovus, 
Ceretrieve, Cook Medical, Gentuity, Imperative Care, InNeuroCo, Magneto, Microvention, 
Medtronic Neurovascular, MIVI Neurosciences, Neuravi, Neurogami, Philips Healthcare, 
Rapid Medical, Route 92 Medical, Stryker Neurovascular, Syntheon, and the Wyss 
Institute. 
 
Running headline: Infarct Evolution in a Canine Stroke Model 
 
 
Abstract 
Mechanical thrombectomy for the treatment of ischemic stroke shows high rates 
of recanalization; however, some patients still have a poor clinical outcome. A proposed 
reason for this relates to the fact that the ischemic infarct growth differs significantly 
between patients. While some patients demonstrate rapid evolution of their infarct core 
(fast evolvers), others have substantial potentially salvageable penumbral tissue even 
hours after initial vessel occlusion (slow evolvers). We show that the dog middle cerebral 
artery occlusion model recapitulates this key aspect of human stroke rendering it a highly 
desirable model to develop novel multimodal treatments to improve clinical outcomes. 
Moreover, this model is well suited to develop novel image analysis techniques that allow 
for improved lesion evolution prediction; we provide proof-of-concept that MRI perfusion-
based time-to-peak maps can be utilized to predict the rate of infarct growth as validated 
by apparent diffusion coefficient derived lesion maps allowing reliable classification of 
dogs into fast versus slow evolvers enabling more robust study design for interventional 
research. 
Key words: dog, middle cerebral artery occlusion, infarct growth rate, perfusion MRI, 
time-to-peak, stroke.  
Introduction 
In recent years, randomized-controlled trials have shown that mechanical 
thrombectomy is a highly effective treatment for selected ischemic stroke patients with 
emergent large vessel occlusion (ELVO) [1-3]. Although clinical trials and uncontrolled 
stroke registries report successful recanalization of the primary artery in approximately 
85% [4, 5], rates of good clinical outcomes have not yet matched the high rate of technical 
success. For this reason, novel approaches to multimodal intervention that includes 
neuroprotection, adjunctive technology to augment brain perfusion, thrombolysis, and 
recanalization with thrombectomy promise to maximize the probability of a good clinical 
outcome after ELVO. In particular, methods that can slow infarct progression may expand 
the availability of mechanical thrombectomy for ELVO patients that present beyond 
established treatment windows [6, 7]. Approaches under development include transient 
aortic occlusion [8], stimulation of circle of Willis nerve fibers [9], mild induced 
hypertension [10], and inhalation of nitric oxide [11]. Perhaps the greatest opportunity is 
re-exploration of pharmacological neuroprotection combined with mechanical 
thrombectomy [12-15]. 
Although multiple animal stroke models are available in a variety of species to 
study stroke pathophysiology and possible treatment modalities [16], only larger animal 
species such as rabbits [17], non-human primates [18, 19], and dogs [20-27] are suitable 
for creating ELVO via an endovascular approach without performing a craniotomy. 
However, to date only the dog model allows simulation of mechanical thrombectomy for 
ELVO [28]. Moreover, the gyrencephalic brain of dogs renders it structurally and 
functionally more similar to the human brain than that of rodents [29]. Unlike sheep [30, 
31] and swine [32], dogs do not possess a rete mirabile, thus allowing direct endovascular 
access to the middle cerebral artery (MCA) for creating an occlusion as well as achieving 
mechanical recanalization [28, 33, 34]. The dog ELVO model has been developed to 
allow for the assessment of neuroprotectants and other novel therapeutics [35]. Prior 
studies suggested that the dog model may be limited by its variable ischemic lesion 
evolution possibly due to irregular collateral circulation [36, 37]. Here we formally explored 
the possibility that this variability is similar to the human condition and contributes to the 
different rates of infarct evolution [38]: 1.) fast progressors, who experience rapid infarct 
growth with a large ischemic core and failing collaterals despite an early diagnosis within 
6 h of stroke onset [39, 40]; and 2) slow progressors, who experience slow infarct growth 
maintaining a small ischemic core and good collaterals with significant salvageable tissue 
beyond the 6 h time window [41, 42]. 
Diffusion- (DWI) and perfusion-weighted imaging (PWI) are common magnetic 
resonance imaging (MRI) techniques used for diagnosing ischemic stroke in the clinical 
setting [43-49]. The DWI-derived apparent diffusion coefficient (ADC) of cerebral tissue 
decreases within the region of the irreversibly injured infarct core that can be detected 
using appropriate thresholds [50-52]. Several PWI parameters derived from dynamic 
susceptibility contrast (DSC)-MRI including cerebral blood flow (CBF), cerebral blood 
volume (CBV), mean transit time (MTT), time of maximum value of the tissue residue 
function (Tmax), bolus arrival time (BAT), and time-to-peak (TTP) concentration become 
altered as normal cerebral tissue progresses from ischemia to infarction [53]. The 
DWI/PWI mismatch has been used to predict the extent of infarction and identify patients 
likely to benefit from reperfusion therapy [54, 55]. However, depending on the PWI 
parameter used and the method implemented to compute it, studies have reported an 
inconsistency in the identification of the final infarct volume especially when using 
parameters like CBF and MTT [53, 56-68]. On the other hand, PWI parameters like Tmax 
and TTP have been shown to more accurately estimate the final infarct size [54, 69-77]. 
 The DEFUSE 2 clinical trials reliably showed that patients with target mismatch 
(based on Tmax thresholds) who underwent early reperfusion after endovascular stroke 
treatment had more favorable clinical outcomes compared to patients without target 
mismatch [78]. In a previous dog ELVO model an infarct growth model was developed to 
predict the infarct growth rate and final infarct volume based on DWI lesion volume and 
pial collateral quantification from computed tomography (CT) angiograms [37]. However, 
this model was based on fast evolvers and thus it is uncertain whether results can be 
translated to slow evolvers. The ability to differentiate fast from slow evolvers early on is 
an important issue to minimize bias in studies utilizing the dog model to assess novel 
treatment approaches. To address this issue, we leveraged the presence of slow versus 
fast evolving ischemic lesions in our established dog ELVO model to predict the infarct 
evolution using PWI-based TTP maps, derived from DSC-MRI, based only on the first 
PWI image acquired after the onset of stroke. Correct classification of the infarct evolution 
from study inception has the advantage to exclude one type of progressor or to 
prospectively enter animals into appropriate cohorts in therapeutic studies, thereby 
increasing the scientific rigor. 
 
Materials and Methods 
Animal preparation 
All animal research procedures were performed as approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical 
School (Worcester, MA, USA). Fourteen purpose-bred dogs (8 females and 6 males; 
weight: 8.2–23.9 kg; age: 6.5–36 months) were used in this study. Details of the subject 
demographics are provided in Table 1. On the day of surgery, the animals were sedated 
and pre-treated with a single dose of intramuscular acepromazine (0.06 mg/kg), 
buprenorphine (0.02 mg/kg), and glycopyrrolate (0.01 mg/kg). Anesthesia was induced 
with an intravenous dose of propofol (3–4 mg/kg), and the animal was intubated. 
Anesthesia was maintained by mechanical ventilation with 1–3% isoflurane in air. 
Throughout anesthesia, animals were monitored by electrocardiogram (ECG), peripheral 
capillary oxygen saturation (spO2), invasive or non-invasive arterial blood pressure, rectal 
temperature, and end-tidal CO2. All vital measurements were maintained within the 
physiological range [79]. Using a modified Seldinger technique, an 8F hemostatic 
introducer was placed in the right femoral artery to allow endovascular access and blood 
draw for preparing blood clots as previously described in detail [28]. A 6-french Navien-
072 catheter (Medtronic Neurovascular, Irvine, CA) was navigated under fluoroscopic 
guidance to the origin of the right or left internal carotid artery (ICA), at which point an 
autologous clot [28] was injected and advanced to permanently occlude the MCA (Fig. 
1). The side of clot injection was selected on the basis of the larger diameter and length 
of non-tortuous cervical ICA for delivery of this relatively large catheter. 
Imaging protocol 
Once correct clot placement at the origin of the MCA was confirmed by fluoroscopy 
(Allura Xper FD20; Philips Healthcare, Best, the Netherlands), the animal was transferred 
to the MRI scanner (Phillips Achieva/Phillips Ingenia 3T, Philips Healthcare), which is 
physically adjacent to the angiography suite. An 8-channel knee coil (Philips Healthcare) 
was used to acquire the brain scans. The imaging protocol included time-of-flight (ToF) 
imaging (TR/TE 20/4 ms, FA = 20o, matrix 332 × 212), DWI (TR/TE 2600/76 ms, FA = 
90o, b-value = 0, 1000 s/mm2, NSA = 6, matrix 144 × 144), PWI (TR/TE 1500/20.1 ms, 
FA = 40o, 60 dynamics, matrix 320 × 320), and T2-weighted (T2W)-FLAIR imaging 
(TR/TE 11000/125 ms, TI 2800 ms, FA = 90o, ETL = 27, matrix = 288 × 288). FLAIR 
imaging was used to rule out the possibility of subarachnoid hemorrhage. For PWI, 0.2 
mmol/kg of gadopentetate dimeglumine (Magnevist, Bayer Healthcare Pharmaceuticals, 
Leverkusen, Germany) was injected intravenously (IV) after the second of 60 dynamic 
scans (total scan time = 90 s), followed by 15 ml saline bolus. DWI was obtained 
approximately every half hour up to 4.5 h post-clot injection. To calculate the infarct core 
volume, ADC maps were generated from the DWI images. Once the final diffusion image 
was acquired, the animal was euthanized, and in selected cases the brain was harvested 
immediately for histological assessment to confirm the final infarct size.   
Image analysis 
In order to assess the rate of infarct evolution based on DWI images, ADC maps 
were generated using MATLAB (The Mathworks, Inc., Natick, MA) and the datasets were 
binned in aggregates of 30 min. Since the goal of the study was to assess the rate of 
infarct evolution rather than the overall size of the infarct, the infarct size at each time-
point was normalized by the final volume. When DWI was unavailable at a time point, 
linear interpolation was used to estimate the size of the normalized infarct. 
Calculation of TTP maps was done offline using ImageJ (Rasband W. ImageJ. 
Bethesda, MD: http://rsb.info.nih.gov/ij/; 1997–2006) and MATLAB. The dynamic scans 
from PWI were used to segment the entire brain region in ImageJ. Scripts were written in 
MATLAB to calculate the TTP maps using the segmented brain slices from the dynamic 
scans on a voxel-by-voxel basis by locating the dynamic scan that contained the minimum 
intensity value. To obtain a relative TTP (rTTP) map, TTP maps were normalized by 
subtracting the mean TTP derived from a contralateral region of interest (ROI; positioned 
in the periventricular area of the unaffected hemisphere in the mid-brain region) from the 
absolute TTP in each voxel using the following equation: 
𝑟𝑇𝑇𝑃𝑚𝑎𝑝 = 𝑇𝑇𝑃𝑚𝑎𝑝 −
1
𝑛
∑(𝑅𝑂𝐼𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙)𝑖
𝑛
𝑖=1
 
where n is the total number of voxels in the contralateral ROI.  
To allow for exact voxel-wise analysis, all brain slices from the respective ADC and 
TTP maps were co-registered prior to analysis. This was accomplished by registering the 
B0 images from the DWI acquisition to the raw PWI images using a Dice similarity 
coefficient to confirm the best possible registration. This affine transformation was then 
applied to the ADC maps, which registered them to the rTTP maps. The areas defined as 
infarct on the final DWI were used to isolate only the voxels within the rTTP maps that 
ultimately evolved to infarction. The voxels on the rTTP maps were categorized into 4 
bins: 4‒8 s (slight delay), 9‒13 s (moderate delay), 14‒18 s (long delay), and 19+ s 
(extended delay). This categorization was used to predict the rate of infarct evolution 
using the rTTP maps and comparing them to the true rate of infarct evolution as measured 
using serial DWI. A summary of the image analysis is shown in Fig. 2. An rTTP infarct 
evolution (rTTPIE) index was also calculated using the ratio of the rTTP map voxels in 
the extended delay and slight delay bins to quantify the rate of infarct evolution in fast and 
slow evolvers (Table 1). An rTTPIE index greater than 1 would indicate a fast evolver and 
less than 1 would indicate a slow evolver. 
Final infarct determination 
To minimize confounding of MRI to histology-determined infarct size, we used the 
ADC-thresholded core assessed on the final image set to determine final infarct volume, 
which has been previously shown to have a high correlation with TTC-based histology 
[80, 81]. In addition, we used a subset of animals to assess the final infarct volume 
histologically. Following extraction, brains were placed in a -80°C freezer for 
approximately 20 min and then cut into approximately 5-mm thick sections. Each section 
was stained with 2,3,5-triphenyltetrazolium (TTC) for final infarct volume assessment.  
Statistical analysis 
All statistical analyses were done in R (R Development Core Team (2018). R: A 
Language and Environment for Statistical Computing (Version 3.5.2) [Software]. Vienna, 
Austria: R Foundation for Statistical Computing. Retrieved from http://www.R-project.org). 
For demographic data, analysis of variance (ANOVA) was used to identify any differences 
between the slow and fast evolvers. The Pearson product–moment correlation coefficient 
was used to check for significance of the correlations between the infarct volumes of the 
DWI and PWI images. For the comparison between histograms of the two groups (slow 
and fast evolvers), a paired t-test was used. Fisher’s exact test was used to examine the 
significance of association between the rTTP map and DWI categorization of fast and 
slow evolvers, i.e. to identify the capability of the rTTP maps to predict the DWI results. A 
two-sided p < 0.05 was considered significant in all analyses. A post-hoc power analysis 
was also performed using α = 0.05 to verify the statistical power of the significant 
differences between the fast and slow evolvers in this study using the G*Power software 
package [82]. 
 
Results 
MCA occlusion 
Embolic MCA occlusion was successfully induced in all animals (n = 14) as 
confirmed by digital subtraction angiography (Fig. 1a, b). The persistence of the MCA 
occlusion was confirmed by ToF-MRI (Fig. 1c) in each animal. None of the animals 
displayed any hemorrhagic transformation (data not shown). 
Imaging characteristics of fast evolvers 
Figure 3 depicts a representative animal (Animal #4 from Table 1) that was 
assigned to the fast evolver group (based on the DWI designation discussed below). A 
single coronal slice is shown indicating an area of restricted diffusion in the right MCA 
territory (Fig. 3a). The corresponding ADC map of the same slice shows a hypointense 
region indicating the extent of infarct with a lesion averaged ADC value of ~0.5 × 10-3 
mm2/s (Fig. 3b). The corresponding TTC-stained brain section shows concordance of the 
histology with the ADC-defined region of infarction (Fig. 3c). The rTTP map, 
corresponding to the ADC map, derived from PWI images is displayed using a pseudo-
color map indicating the same infarct region (Fig. 3d). The color intensity of the voxels 
indicates that the infarct area with an elevated intensity are at or above ~20 s. Images 
from DSA in the early (Fig. 3e) and delayed (Fig. 3f) phase indicate a lack of collaterals 
in the right hemisphere. 
Imaging characteristics of slow evolvers 
Figure 4 shows a representative animal (Animal #1 from Table 1) that was 
assigned to the slow evolver group (based on the DWI designation discussed below), 
which revealed a smaller lesion size compared to the fast evolver in Fig. 3. A single 
coronal slice is shown where the infarct region is visible as an area of restricted diffusion 
in the left hemisphere (Fig. 4a). The corresponding ADC map of the same slice shows a 
hypointense region indicating the extent of infarct with an ADC value of ~0.5 × 10-3 mm2/s 
(Fig. 4b). The corresponding TTC-stained brain section confirms the ADC-defined region 
of infarct (Fig. 4c). The TTP map, corresponding to the slice from the ADC map, derived 
from PWI images is displayed using a pseudo-color map indicating the same infarct 
region (Fig. 4d). The color intensity of the voxels in the infarct area only have a slightly 
elevated intensity with only a few voxels above ~20 s, which is in contrast to the elevated 
intensities observed in the fast evolver (Fig. 3d). Images from DSA in the early (Fig. 4e) 
and delayed (Fig. 4f) phase highlight the impact of the collaterals in the left hemisphere. 
Fast and slow evolver designation using DWI 
Based on the normalized infarct volume as a function of time using DWI (Fig. 5a), 
animals were categorized to fast versus slow evolvers. After MCA occlusion, fast evolvers 
showed a constant growth in the ADC-thresholded infarct volume during the first 2 h at 
which point infarct growth plateaued to reach the final infarct size. Slow evolvers 
demonstrated a relatively slow infarct core evolution in the first 2 h with a secondary more 
rapid constant growth occurring afterwards until the final infarct size was reached at 
approximately 4 h after MCA occlusion. Thus, animals displaying more than 50% of total 
infarct volume within 2 h were assigned to the fast evolver group and animals displaying 
less than 50% of the total infarct volume within 2 h were assigned to the slow evolver 
group. Based on this definition, each animal in this study was designated with an infarct 
evolution rate (Table 1). A comparison between the demographics (sex, age, and weight) 
of the fast and slow evolvers did not show any significant difference (Table 2). The vital 
measurements between the groups also did not show any significant difference (data not 
shown) 
Prediction of fast versus slow evolvers using initial PWI 
The correlation plot (Fig. 5b) shows the agreement of the infarct volumes between 
the final DWI image and the TTP map generated from the initial PWI images (R2 = 0.99). 
Based on the relative number of voxels within the “slight delay” and “extended delay” 
categories, animals were classified into fast and slow evolvers (Fig. 5c): the respective 
cutoff marks to distinguish between slow and fast evolvers were ~34% for the “slight 
delay” and ~42% for the “extended delay” bins based on the minimal distance (halfway 
point) between the boundary points of each category. This classification was more 
apparent using the rTTPIE index, which demonstrated a significant difference between 
the fast and slow evolvers (Table 2). For the remaining bins, the fast and slow evolvers 
did not show a significant difference. This rTTP-based classification correctly predicted 
the DWI results of all fourteen animals (p < 0.01, Fishers exact test for classification). The 
post-hoc analyses for this study revealed the statistical power to exceed 0.99 for the 
detection of differences between the fast and slow evolvers using the “slight delay” and 
“extended delay” bins, and the rTTPIE index. 
Ex vivo infarct assessment and correlation with MRI 
In a subset of dogs (n = 6: 4 fast evolvers and 2 slow evolvers) after euthanasia, 
the brain was removed to histologically quantify the infarct volume using TTC. Overall, 
there was an excellent correlation between the final ADC-thresholded and the TTC-
defined infarct volume (R2 = 0.99) with a slope of 0.96 (data not shown). 
 
Discussion 
During human ELVO, the rate of infarct growth is determined by a combination of 
factors such as genetic background, demographics, physiological parameters, and other 
conditions that may influence collateral blood flow and ischemic tolerance [5, 38]. A key 
finding of our study was that the dog ELVO model, similar to monkeys [19], is 
characterized by variability in the ischemic stroke evolution that closely mimics the clinical 
scenario [38]. This phenomenon, in conjunction with the ability to study endovascular 
approaches to recanalization, renders the dog ELVO model as highly relevant to study 
novel therapeutic approaches in interventional research. Importantly, we show that voxel-
wise analyses of PWI images allow to predict whether animals were fast or slow evolvers 
already on the first PWI scan obtained approximately 30 min after MCA occlusion.  
Perfusion is a critical biological mechanism that reflects the delivery of oxygen and 
essential nutrients to tissue via blood flow. MR-based PWI has the potential to measure 
brain perfusion in acute stroke subjects and provide treatment options that may 
significantly affect the clinical outcome. DSC-MRI, compared to other PWI techniques like 
dynamic contrast-enhanced (DCE)-MRI and arterial-spin labeling (ASL), offers faster 
scan times to get a quick measurement of transit time with whole brain coverage, which 
can be critical in driving treatment decisions with a limited time window [83]. The 
deconvolved PWI parameters derived from DSC-MRI such as CBF, CBV, and MTT, have 
been considered to be more reliable in detecting tissue at risk of infarction due to the use 
of an arterial input function (AIF), which takes into account any variations in physiological 
and injection conditions [84, 85]. However, the AIF shape is susceptible to errors due to 
several factors such as motion artifacts and partial volume effects among others.[86, 87] 
Non-deconvolved PWI parameters derived from DSC-MRI such as TTP and BAT, on the 
other hand, do not require the measurement of an AIF and are derived directly from the 
tissue concentration time curve without any deconvolution. 
TTP has been suggested to rapidly identify tissue at risk of infarction (penumbral 
tissue) and predict infarct size and growth in stroke patients [73, 75, 76, 88-91]. 
Thresholds of TTP delay (TTP > 4 s best identifying penumbral flow) [54, 72-76, 88, 92] 
were used to determine the volume of tissue that would become viable or that were at 
risk to progress to infarct. These TTP thresholds have been compared with 15O-water 
positron emission tomography (PET) studies and validated using 15O-water PET-derived 
CBF threshold of <20 ml/100 g/min, which serves as the “gold standard” for detecting 
penumbral tissue in ischemic stroke [57, 74-76, 92, 93]. In this study, we expanded the 
role of TTP maps to assess the extent of critically hypoperfused brain tissue as well as to 
predict the rate of infarct evolution. 
TTP maps have been generated in several different ways in clinical and animal 
studies over the last couple of decades. TTP map calculations have mainly been reported 
using three different methods where: 1.) TTP was defined as the time difference in peak 
intensity and the BAT [85, 94]; 2.) TTP was defined as the time from bolus injection to 
peak intensity [53, 54, 76, 95]; and 3.) TTP maps were generated using a normalization 
by subtracting a mean contralateral ROI of the unaffected hemisphere [54, 71-73, 75]. 
Since the latter method using normalization of the TTP map reduces AIF dependency (by 
lowering variability due to factors such as injection rate, catheter size, and cardiac output 
among others) and performs as well as deconvolved parameters in infarct prediction [57, 
85, 86, 96], we used rTTP maps in this study to perform the histogram binning. 
Histogram binning of rTTP maps successfully classified the animals into fast and 
slow evolvers based on the infarct growth rate observed in the ADC maps. The “slight 
delay” and “extended delay” bins in the histogram clearly distinguished between the fast 
and slow evolvers, which is numerically evident using the rTTPIE index. Utilizing the rTTP 
map binning scheme promises to be useful in prospectively determining whether an 
animal will progress as a fast or slow evolver ‒ a major advantage when studying novel 
therapeutics as it would allow to control for variability in infarct progression as part of the 
randomization scheme. 
 
Limitations 
 One limitation from our analysis was that only two types of evolvers (fast and slow) 
were distinguishable using the rTTP analysis. If the rTTPIE index value equaled close to 
one, then that would correspond to having approximately equal number of voxels in the 
“slight delay” and “extended delay” histogram bins of the rTTP maps, which would make 
it difficult to assign the animal as a fast or slow evolver. In that case, an “intermediate 
evolver” designation maybe more appropriate. The rTTP analysis to predict fast and slow 
evolvers was done retrospectively, which requires prospective confirmation of these 
preliminary findings. There was a notable variation in animal age and weight related to 
the different strains of dogs included into our retrospective analysis. However, we did not 
find any significant age and weight difference between fast and slow evolvers, assuaging 
concerns of major confounding and may in fact indicate broad applicability of our results. 
During the course of this proof-of-concept study, histology was not performed in all dogs 
for confirmation of the ADC thresholded infarct volume. However, in our past experience, 
the selected ADC threshold is highly concordant with histology [27, 28].  
 
Conclusion 
The canine model of embolic stroke resulting in the occlusion of the MCA results 
in both slow and fast infarct evolution. Preliminary evidence demonstrates that infarct 
evolution pattern can be determined immediately after clot placement using perfusion-
weighted MRI. These data support more robust preclinical assessment of complex, 
multimodal acute stroke therapies. 
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Figure Legends 
 
Fig. 1 Placement of an autologous clot in the middle cerebral artery (MCA) of the dog. (a) 
Digital Subtraction Angiography (DSA) prior to clot placement is shown. The arrows 
indicate the location of the MCA (b) Total MCA occlusion is shown in DSA post-clot 
placement. The dashed arrows depict the original course of the MCA, which is now 
absent.  (c) Time-of-flight (ToF) MRI shows an open internal carotid artery (ICA) and an 
occluded MCA. 
 
Fig. 2 Flowchart of image analysis. Apparent diffusion coefficient (ADC) and time-to-peak 
(TTP) maps were generated from diffusion-weighted imaging (DWI) and perfusion-
weighted imaging (PWI), respectively. ADC maps were used to calculate the final infarct 
volume. The entire brain in TTP maps was normalized with respect to a representative 
area on the contralateral side of the infarct region to generate relative TTP (rTTP) maps. 
rTTP maps were registered with ADC maps to count the voxels within the infarct volume. 
All voxels within the ADC-defined lesion were binned into one of four categories in the 
rTTP map. The total size of each bin, across the entire lesion volume, was used to predict 
the rate of infarct evolution. 
 
Fig. 3 Representative animal from the fast evolver group (Animal #4 from Table 1). (a) 
Final diffusion-weighted imaging (DWI) image showing the total extent of the infarct as a 
hyperintense region. (b) Apparent diffusion coefficient (ADC) map showing a hypointense 
region indicating the extent of infarct. The red line on the scale bar indicates the intensity 
level of the infarct region. (c) Post-mortem triphenyltetrazolium chloride (TTC) staining 
showing the final histological infarct size. Scale bar: 10 mm. (d) Relative time-to-peak 
(rTTP) map derived from perfusion-weighted imaging (PWI) images. The color intensity 
of the infarct area voxels indicate an elevated intensity at or above the 20-s delay. Digital 
Subtraction Angiography (DSA) is shown in early (e) and delayed phase (f), which denote 
a lack of collaterals in the right hemisphere. The arrows indicate the location of the clot. 
 
Fig. 4 Representative animal from the slow evolver group (Animal #1 from Table 1). (a) 
Final diffusion-weighted imaging (DWI) image showing the total extent of the infarct as a 
hyperintense region. (b) Apparent diffusion coefficient (ADC) map showing a hypointense 
region indicating the extent of infarct. The red line on the scale bar indicates the intensity 
level of the infarct region. (c) Post-mortem triphenyltetrazolium chloride (TTC) staining 
showing the final histological infarct size. Scale bar: 10 mm. (d) Relative time-to-peak 
(rTTP) map derived from perfusion-weighted imaging (PWI) images. The area of 
occlusion is seen only slightly elevated with a few voxels above the 20-s delay. Digital 
Subtraction Angiography (DSA) is shown in early (e) and delayed phase (f), which 
highlights the impact of the collaterals in the left hemisphere. The arrows indicate the 
location of the clot. 
 
Fig. 5 Quantification of fast and slow evolvers using diffusion-weighted imaging (DWI) 
apparent diffusion coefficient (ADC) maps and perfusion-weighted imaging (PWI) time-
to-peak (TTP) maps. (a) Ischemic core evolution as derived by ADC-thresholded maps 
and dichotomized to fast (orange) versus slow (blue) evolvers are shown. Based on lesion 
growth rate, animals were divided into fast (>50% total volume within 2 h) and slow (<50% 
total volume within 2 h) evolver groups. The plot shows the progression of slow and fast 
evolvers with the greatest difference occurring at about 2 h. Individual growth curves are 
shown for each animal in lighter shade. Error bars indicate SEM. (b) Correlation plot is 
shown indicating the agreement of infarct volumes between the final DWI image and the 
TTP map generated from the initial PWI images (R2 = 0.99). The dotted lines indicate 
95% confidence level. (c) Histogram binning from rTTP maps for fast and slow evolvers 
are shown. The voxels in the “slight delay” bin (4−8 s) of fast evolvers are significantly 
fewer compared to that of slow evolvers (**p < 0.0001). The dashed line near the left axis 
of the plot shows a cutoff at ~34%, which distinguishes between the fast and slow 
evolvers in the “slight delay” bin. The voxels in the “extended delay” bin (19+ s) of fast 
evolvers are significantly more compared to that of slow evolvers (*p = 0.0013). The 
dashed line near the right axis of the plot shows a cutoff at ~42%, which distinguishes 
between the fast and slow evolvers in the “extended delay” bin. The two middle bins of 
“moderate delay” (9−13 s) and “long delay” (14−18 s) did not show any significant 
differences between the slow and fast evolvers. Error bars indicate SEM.  
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Running headline: Infarct Evolution in a Canine Stroke Model 
 
 
Abstract 
Mechanical thrombectomy for the treatment of ischemic stroke shows high rates 
of recanalization; however, some patients still have a poor clinical outcome. A proposed 
reason for this relates to the fact that the ischemic infarct growth differs significantly 
between patients. While some patients demonstrate rapid evolution of their infarct core 
(fast evolvers), others have substantial potentially salvageable penumbral tissue even 
hours after initial vessel occlusion (slow evolvers). We show that the dog middle cerebral 
artery occlusion model recapitulates this key aspect of human stroke rendering it a highly 
desirable model to develop novel multimodal treatments to improve clinical outcomes. 
Moreover, this model is well suited to develop novel image analysis techniques that allow 
for improved lesion evolution prediction; we provide proof-of-concept that MRI perfusion-
based time-to-peak maps can be utilized to predict the rate of infarct growth as validated 
by apparent diffusion coefficient derived lesion maps allowing reliable classification of 
dogs into fast versus slow evolvers enabling more robust study design for interventional 
research. 
Key words: dog, middle cerebral artery occlusion, infarct growth rate, perfusion MRI, 
time-to-peak, stroke.  
Introduction 
In recent years, randomized-controlled trials have shown that mechanical 
thrombectomy is a highly effective treatment for selected ischemic stroke patients with 
emergent large vessel occlusion (ELVO) [1-3]. Although clinical trials and uncontrolled 
stroke registries report successful recanalization of the primary artery in approximately 
85% [4, 5], rates of good clinical outcomes have not yet matched the high rate of technical 
success. For this reason, novel approaches to multimodal intervention that includes 
neuroprotection, adjunctive technology to augment brain perfusion, thrombolysis, and 
recanalization with thrombectomy promise to maximize the probability of a good clinical 
outcome after ELVO. In particular, methods that can slow infarct progression may expand 
the availability of mechanical thrombectomy for ELVO patients that present beyond 
established treatment windows [6, 7]. Approaches under development include transient 
aortic occlusion [8], stimulation of circle of Willis nerve fibers [9], mild induced 
hypertension [10], and inhalation of nitric oxide [11]. Perhaps the greatest opportunity is 
re-exploration of pharmacological neuroprotection combined with mechanical 
thrombectomy [12-15]. 
Although multiple animal stroke models are available in a variety of species to 
study stroke pathophysiology and possible treatment modalities [16], only larger animal 
species such as rabbits [17], non-human primates [18, 19], and dogs [20-27] are suitable 
for creating ELVO via an endovascular approach without performing a craniotomy. 
However, to date only the dog model allows simulation of mechanical thrombectomy for 
ELVO [28]. Moreover, the gyrencephalic brain of dogs renders it structurally and 
functionally more similar to the human brain than that of rodents [29]. Unlike sheep [30, 
31] and swine [32], dogs do not possess a rete mirabile, thus allowing direct endovascular 
access to the middle cerebral artery (MCA) for creating an occlusion as well as achieving 
mechanical recanalization [28, 33, 34]. The dog ELVO model has been developed to 
allow for the assessment of neuroprotectants and other novel therapeutics [35]. Prior 
studies suggested that the dog model may be limited by its variable ischemic lesion 
evolution possibly due to irregular collateral circulation [36, 37]. Here we formally explored 
the possibility that this variability is similar to the human condition and contributes to the 
different rates of strokeinfarct evolution [38]: 1.) fast progressors, who experience rapid 
infarct growth with a large ischemic core and failing collaterals despite an early diagnosis 
within 6 h of stroke onset [39, 40]; and 2) slow progressors, who experience slow infarct 
growth maintaining a small ischemic core and good collaterals with significant 
salvageable tissue beyond the 6 h time window [41, 42]. 
Diffusion- (DWI) and perfusion-weighted imaging (PWI) are common magnetic 
resonance imaging (MRI) techniques used for diagnosing ischemic stroke in the clinical 
setting [43-49]. The DWI-derived apparent diffusion coefficient (ADC) of cerebral tissue 
decreases within the region of the irreversibly injured infarct core that can be detected 
using appropriate thresholds [50-52]. Several PWI parameters derived from dynamic 
susceptibility contrast (DSC)-MRI including cerebral blood flow (CBF), cerebral blood 
volume (CBV), mean transit time (MTT), time of maximum value of the tissue residue 
function (Tmax), bolus arrival time (BAT), and time-to-peak (TTP) concentration become 
altered as normal cerebral tissue progresses from ischemia to infarction [53]. The 
DWI/PWI mismatch has been used to predict the extent of infarction and identify patients 
likely to benefit from reperfusion therapy [54, 55]. However, depending on the PWI 
parameter used and the method implemented to compute it, studies have reported an 
inconsistency in the identification of the final infarct volume especially when using 
parameters like CBF and MTT [53, 56-68]. On the other hand, PWI parameters like Tmax 
and TTP have been shown to more accurately estimate the final infarct size [54, 69-77]. 
 The DEFUSE 2 clinical trials reliably showed that patients with target mismatch 
(based on Tmax thresholds) who underwent early reperfusion after endovascular stroke 
treatment had more favorable clinical outcomes compared to patients without target 
mismatch [78]. In a previous dog ELVO model an infarct growth model was developed to 
predict the infarct growth rate and final infarct volume based on DWI lesion volume and 
pial collateral quantification from computed tomography (CT) angiograms [37]. However, 
this model was based on fast evolvers and thus it is uncertain whether results can be 
translated to slow evolvers. The ability to differentiate fast from slow evolvers early on is 
an important issue to minimize bias in studies utilizing the dog model to assess novel 
treatment approaches. To address this issue, we leveraged the presence of slow versus 
fast evolving ischemic lesions in our established dog ELVO model to predict the infarct 
evolution using PWI-based TTP maps, derived from DSC-MRI, based only on the first 
PWI image acquired after the onset of stroke. Correct classification of the infarct evolution 
from study inception has the advantage to exclude one type of progressor or to 
prospectively enter animals into appropriate cohorts in therapeutic studies, thereby 
increasing the scientific rigor. 
 
Materials and Methods 
Animal preparation 
All animal research procedures were performed as approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical 
School (Worcester, MA, USA). Fourteen purpose-bred dogs (8 females and 6 males; 
weight: 8.2–23.9 kg; age: 6.5–36 months) were used in this study. Details of the subject 
demographics are provided in Table 1. On the day of surgery, the animals were sedated 
and pre-treated with a single dose of intramuscular acepromazine (0.06 mg/kg), 
buprenorphine (0.02 mg/kg), and glycopyrrolate (0.01 mg/kg). Anesthesia was induced 
with an intravenous dose of propofol (3–4 mg/kg), and the animal was intubated. 
Anesthesia was maintained by mechanical ventilation with 1–3% isoflurane in air. 
Throughout anesthesia, animals were monitored by electrocardiogram (ECG), peripheral 
capillary oxygen saturation (spO2), invasive or non-invasive arterial blood pressure, rectal 
temperature, and end-tidal CO2. All vital measurements were maintained within the 
physiological range [79]. Using a modified Seldinger technique, an 8F hemostatic 
introducer was placed in the right femoral artery to allow endovascular access and blood 
draw for preparing blood clots as previously described in detail [28]. A 6-french Navien-
072 catheter (Medtronic Neurovascular, Irvine, CA) was navigated under fluoroscopic 
guidance to the origin of the right or left internal carotid artery (ICA), at which point an 
autologous clot [28] was injected and advanced to permanently occlude the MCA (Fig. 
1). The side of clot injection was selected on the basis of the larger diameter and length 
of non-tortuous cervical ICA for delivery of this relatively large catheter. 
Imaging protocol 
Once correct clot placement at the origin of the MCA was confirmed by fluoroscopy 
(Allura Xper FD20; Philips Healthcare, Best, the Netherlands), the animal was transferred 
to the MRI scanner (Phillips Achieva/Phillips Ingenia 3T, Philips Healthcare), which is 
physically adjacent to the angiography suite. An 8-channel knee coil (Philips Healthcare) 
was used to acquire the brain scans. The imaging protocol included time-of-flight (ToF) 
imaging (TR/TE 20/4 ms, FA = 20o, matrix 332 × 212), DWI (TR/TE 2600/76 ms, FA = 
90o, b-value = 0, 1000 s/mm2, NSA = 6, matrix 144 × 144), PWI (TR/TE 1500/20.1 ms, 
FA = 40o, 60 dynamics, matrix 320 × 320), and T2-weighted (T2W)-FLAIR imaging 
(TR/TE 11000/125 ms, TI 2800 ms, FA = 90o, ETL = 27, matrix = 288 × 288). FLAIR 
imaging was used to rule out the possibility of subarachnoid hemorrhage. For PWI, 0.2 
mmol/kg of gadopentetate dimeglumine (Magnevist, Bayer Healthcare Pharmaceuticals, 
Leverkusen, Germany) was injected intravenously (IV) after the second of 60 dynamic 
scans (total scan time = 90 s), followed by 15 ml saline bolus. DWI was obtained 
approximately every half hour up to 4.5 h post-clot injection. To calculate the infarct core 
volume, ADC maps were generated from the DWI images. Once the final diffusion image 
was acquired, the animal was euthanized, and in selected cases the brain was harvested 
immediately for histological assessment to confirm the final infarct size.   
Image analysis 
In order to assess the rate of strokeinfarct evolution based on DWI images, ADC 
maps were generated using MATLAB (The Mathworks, Inc., Natick, MA) and the datasets 
were binned in aggregates of 30 min. Since the goal of the study was to assess the rate 
of infarct evolution rather than the overall size of the infarct, the infarct size at each time-
point was normalized by the final volume. When DWI was unavailable at a time point, 
linear interpolation was used to estimate the size of the normalized infarct. 
Calculation of TTP maps was done offline using ImageJ (Rasband W. ImageJ. 
Bethesda, MD: http://rsb.info.nih.gov/ij/; 1997–2006) and MATLAB. The dynamic scans 
from PWI were used to segment the entire brain region in ImageJ. Scripts were written in 
MATLAB to calculate the TTP maps using the segmented brain slices from the dynamic 
scans on a pixelvoxel-by-pixelvoxel basis by locating the dynamic scan that contained the 
minimum intensity value. TheTo obtain a relative TTP (rTTP) map, TTP maps were then 
normalized by subtraction of a subtracting the mean TTP derived from a contralateral 
region of interest (ROI); positioned in the periventricular area of the unaffected 
hemisphere in the mid-brain region) from the absolute TTP in each pixel, yielding a 
relative TTP (rTTP) mapvoxel using the following equation: 
𝑟𝑇𝑇𝑃𝑚𝑎𝑝 = 𝑇𝑇𝑃𝑚𝑎𝑝 −
1
𝑛
∑(𝑅𝑂𝐼𝑐𝑜𝑛𝑡𝑟𝑎𝑙𝑎𝑡𝑒𝑟𝑎𝑙)𝑖
𝑛
𝑖=1
 
where n is the total number of voxels in the contralateral ROI.  
To allow for exact voxel-wise analysis, all brain slices from the respective ADC and 
TTP maps were co-registered prior to analysis. This was accomplished by registering the 
B0 images from the DWI acquisition to the raw PWI images using a Dice similarity 
coefficient to confirm the best possible registration. This affine transformation was then 
applied to the ADC maps, which registered them to the rTTP maps. The areas defined as 
infarct on the final DWI were used to isolate only the voxels within the rTTP maps that 
ultimately evolved to infarction. The voxels on the rTTP maps were categorized into 4 
bins: 4‒8 s (slight delay), 9‒13 s (moderate delay), 14‒18 s (long delay), and 19+ s 
(extended delay). This categorization was used to predict the rate of strokeinfarct 
evolution using the rTTP maps and comparing them to the true rate of strokeinfarct 
evolution as measured using serial DWI. A summary of the image analysis is shown in 
Fig. 2. An rTTP stroke rateinfarct evolution (rTTPIE) index (rTTP-SRI) was also calculated 
using the ratio of the rTTP map voxels in the extended delay and slight delay bins to 
quantify the rate of strokeinfarct evolution in fast and slow evolvers (Table 1). An rTTP-
SRIrTTPIE index greater than 1 would indicate a fast evolver and less than 1 would 
indicate a slow evolver. 
Final infarct determination 
To minimize confounding of MRI to histology-determined infarct size, we used the 
ADC-thresholded core assessed on the final image set to determine final infarct volume, 
which has been previously shown to have a high correlation with TTC-based histology 
[80, 81]. In addition, we used a subset of animals to assess the final infarct volume 
histologically. Following extraction, brains were placed in a -80°C freezer for 
approximately 20 min and then cut into approximately 5-mm thick sections. Each section 
was stained with 2,3,5-triphenyltetrazolium (TTC) for final infarct volume assessment.  
Statistical analysis 
All statistical analyses were done in R (R Development Core Team (2018). R: A 
Language and Environment for Statistical Computing (Version 3.5.2) [Software]. Vienna, 
Austria: R Foundation for Statistical Computing. Retrieved from http://www.R-project.org). 
For demographic data, analysis of variance (ANOVA) was used to identify any differences 
between the slow and fast evolvers. The Pearson product–moment correlation coefficient 
was used to check for significance of the correlations between the infarct volumes of the 
DWI and PWI images. For the comparison between histograms of the two groups (slow 
and fast evolvers), a paired t-test was used. Fisher’s exact test was used to examine the 
significance of association between the rTTP map and DWI categorization of fast and 
slow evolvers, i.e. to identify the capability of the rTTP maps to predict the DWI results. A 
two-sided p < 0.05 was considered significant in all analyses. A post-hoc power analysis 
was also performed using α = 0.05 to verify the statistical power of the significant 
differences between the fast and slow evolvers in this study using the G*Power software 
package [82]. 
 
Results 
MCA occlusion 
Embolic MCA occlusion was successfully induced in all animals (n = 14) as 
confirmed by digital subtraction angiography (Fig. 1a, b). The persistence of the MCA 
occlusion was confirmed by ToF-MRI (Fig. 1c) in each animal. None of the animals 
displayed any hemorrhagic transformation (data not shown). 
Imaging characteristics of fast evolvers 
Figure 3 depicts a representative animal (Animal #4 from Table 1) that was 
assigned to the fast evolver group (based on the DWI designation discussed below). A 
single coronal slice is shown indicating an area of restricted diffusion in the right MCA 
territory (Fig. 3a). The corresponding ADC map of the same slice shows a hypointense 
region indicating the extent of infarct with a lesion averaged ADC value of ~0.5 × 10-3 
mm2/s (Fig. 3b). The corresponding TTC-stained brain section shows concordance of the 
histology with the ADC-defined region of infarction (Fig. 3c). The rTTP map, 
corresponding to the ADC map, derived from PWI images is displayed using a pseudo-
color map indicating the same infarct region (Fig. 3d). The color intensity of the voxels 
indicates that the infarct area with an elevated intensity are at or above ~20 s. Images 
from DSA in the early (Fig. 3e) and delayed (Fig. 3f) phase indicate a lack of collaterals 
in the right hemisphere. 
Imaging characteristics of slow evolvers 
Figure 4 shows a representative animal (Animal #1 from Table 1) that was 
assigned to the slow evolver group (based on the DWI designation discussed below), 
which revealed a smaller lesion size compared to the fast evolver in Fig. 3. A single 
coronal slice is shown where the infarct region is visible as an area of restricted diffusion 
in the left hemisphere (Fig. 4a). The corresponding ADC map of the same slice shows a 
hypointense region indicating the extent of infarct with an ADC value of ~0.5 × 10-3 mm2/s 
(Fig. 4b). The corresponding TTC-stained brain section confirms the ADC-defined region 
of infarct (Fig. 4c). The TTP map, corresponding to the slice from the ADC map, derived 
from PWI images is displayed using a pseudo-color map indicating the same infarct 
region (Fig. 4d). The color intensity of the voxels in the infarct area only have a slightly 
elevated intensity with only a few voxels above ~20 s, which is in contrast to the elevated 
intensities observed in the fast evolver (Fig. 3d). Images from DSA in the early (Fig. 4e) 
and delayed (Fig. 4f) phase highlight the impact of the collaterals in the left hemisphere. 
Fast and slow evolver designation using DWI 
Based on the normalized strokeinfarct volume as a function of time using DWI (Fig. 
5a), animals were categorized to fast versus slow evolvers. After MCA occlusion, fast 
evolvers showed a constant growth in the ADC-thresholded infarct volume during the first 
2 h at which point infarct growth plateaued to reach the final infarct size. Slow evolvers 
demonstrated a relatively slow infarct core evolution in the first 2 h with a secondary more 
rapid constant growth occurring afterwards until the final infarct size was reached at 
approximately 4 h after MCA occlusion. Thus, animals displaying more than 50% of total 
infarct volume within 2 h were assigned to the fast evolver group and animals displaying 
less than 50% of the total infarct volume within 2 h were assigned to the slow evolver 
group. Based on this definition, each animal in this study was designated with an infarct 
evolution rate (Table 1). A comparison between the demographics (sex, age, and weight) 
of the fast and slow evolvers did not show any significant difference (Table 2). The vital 
measurements between the groups also did not show any significant difference (data not 
shown) 
Prediction of fast versus slow evolvers using initial PWI 
The correlation plot (Fig. 5b) shows the agreement of the infarct volumes between 
the final DWI image and the TTP map generated from the initial PWI images (R2 = 0.99). 
Based on the relative number of voxels within the “slight delay” and “extended delay” 
categories, animals were classified into fast and slow evolvers (Fig. 5c): the respective 
cutoff marks to distinguish between slow and fast evolvers were ~34% for the “slight 
delay” and ~42% for the “extended delay” bins. based on the minimal distance (halfway 
point) between the boundary points of each category. This classification was more 
apparent using the rTTP-SRIrTTPIE index, which demonstrated a significant difference 
between the fast and slow evolvers (Table 2). For the remaining bins, the fast and slow 
evolvers did not show a significant difference. This rTTP-based classification correctly 
predicted the DWI results of all fourteen animals (p < 0.01, Fishers exact test for 
classification). The post-hoc analyses for this study revealed the statistical power to 
exceed 0.99 for the detection of differences between the fast and slow evolvers using the 
“slight delay” and “extended delay” bins, and the rTTP-SRIrTTPIE index. 
Ex vivo infarct assessment and correlation with MRI 
In a subset of dogs (n = 6: 4 fast evolvers and 2 slow evolvers) after euthanasia, 
the brain was removed to histologically quantify the infarct volume using TTC. Overall, 
there was an excellent correlation between the final ADC-thresholded and the TTC-
defined infarct volume (R2 = 0.99) with a slope of 0.96 (data not shown). 
 
Discussion 
During human ELVO, the rate of infarct growth is determined by a combination of 
factors such as genetic background, demographics, physiological parameters, and other 
conditions that may influence collateral blood flow and ischemic tolerance [5, 38]. A key 
finding of our study was that the dog ELVO model, similar to monkeys [19], is 
characterized by variability in the ischemic stroke evolution that closely mimics the clinical 
scenario [38]. This phenomenon, in conjunction with the ability to study endovascular 
approaches to recanalization, renders the dog ELVO model as highly relevant to study 
novel therapeutic approaches in interventional research. Importantly, we show that voxel-
wise analyses of PWI images allow to predict whether animals were fast or slow evolvers 
already on the first PWI scan obtained approximately 30 min after MCA occlusion.  
Perfusion is a critical biological mechanism that reflects the delivery of oxygen and 
essential nutrients to tissue via blood flow. MR-based PWI has the potential to measure 
brain perfusion in acute stroke subjects and provide treatment options that may 
significantly affect the clinical outcome. DSC-MRI, compared to other PWI techniques like 
dynamic contrast-enhanced (DCE)-MRI and arterial-spin labeling (ASL), offers faster 
scan times to get a quick measurement of transit time with whole brain coverage, which 
can be critical in driving treatment decisions with a limited time window [83]. The 
deconvolved PWI parameters derived from DSC-MRI such as CBF, CBV, and MTT, have 
been considered to be more reliable in detecting tissue at risk of infarction due to the use 
of an arterial input function (AIF), which takes into account any variations in physiological 
and injection conditions [84, 85]. However, the AIF shape is susceptible to errors due to 
several factors such as motion artifacts and partial volume effects among others.[86, 87] 
Non-deconvolved PWI parameters derived from DSC-MRI such as TTP and BAT, on the 
other hand, do not require the measurement of an AIF and are derived directly from the 
tissue concentration time curve without any deconvolution. 
TTP has been suggested to rapidly identify tissue at risk of infarction (penumbral 
tissue) and predict infarct size and growth in stroke patients [73, 75, 76, 88-91]. 
Thresholds of TTP delay (TTP > 4 s best identifying penumbral flow) [54, 72-76, 88, 92] 
were used to determine the volume of tissue that would become viable or that were at 
risk to progress to infarct. These TTP thresholds have been compared with 15O-water 
positron emission tomography (PET) studies and validated using 15O-water PET-derived 
CBF threshold of <20 ml/100 g/min, which serves as the “gold standard” for detecting 
penumbral tissue in ischemic stroke [57, 74-76, 92, 93]. In this study, we expanded the 
role of TTP maps to assess the extent of critically hypoperfused brain tissue as well as to 
predict the rate of strokeinfarct evolution. 
TTP maps have been generated in several different ways in clinical and animal 
studies over the last couple of decades. TTP map calculations have mainly been reported 
using three different methods where: 1.) TTP was defined as the time difference in peak 
intensity and the BAT [85, 94]; 2.) TTP was defined as the time from bolus injection to 
peak intensity [53, 54, 76, 95]; and 3.) TTP maps were generated using a normalization 
by subtracting a mean contralateral ROI of the unaffected hemisphere [54, 71-73, 75]. 
Since the latter method using normalization of the TTP map reduces AIF dependency (by 
lowering variability due to factors such as injection rate, catheter size, and cardiac output 
among others) and performs as well as deconvolved parameters in infarct prediction [57, 
85, 86, 96], we used rTTP maps in this study to perform the histogram binning. 
Histogram binning of rTTP maps successfully classified the animals into fast and 
slow evolvers based on the infarct growth rate observed in the ADC maps. The “slight 
delay” and “extended delay” bins in the histogram clearly distinguished between the fast 
and slow evolvers, which is numerically evident using the rTTP-SRIrTTPIE index. Utilizing 
the rTTP map binning scheme promises to be useful in prospectively determining whether 
an animal will progress as a fast or slow evolver ‒ a major advantage when studying novel 
therapeutics as it would allow to control for variability in infarct progression as part of the 
randomization scheme. 
 
Limitations 
 One limitation from our analysis was that only two types of evolvers (fast and slow) 
were distinguishable using the rTTP analysis. If the rTTP-SRIrTTPIE index value equaled 
close to one, then that would correspond to having approximately equal number of voxels 
in the “slight delay” and “extended delay” histogram bins of the rTTP maps, which would 
make it difficult to assign the animal as a fast or slow evolver. In that case, an 
“intermediate evolver” designation maybe more appropriate. The rTTP analysis to predict 
fast and slow evolvers was done retrospectively, which requires prospective confirmation 
of these preliminary findings. There was a notable variation in animal age and weight 
related to the different strains of dogs included into our retrospective analysis. However, 
we did not find any significant age and weight difference between fast and slow evolvers, 
assuaging concerns of major confounding and may in fact indicate broad applicability of 
our results. During the course of this proof-of-concept study, histology was not performed 
in all dogs for confirmation of the ADC thresholded infarct volume. However, in our past 
experience, the selected ADC threshold is highly concordant with histology [27, 28].  
 
Conclusion 
The canine model of embolic stroke resulting in the occlusion of the MCA results 
in both slow and fast infarct evolution. Preliminary evidence demonstrates that infarct 
evolution pattern can be determined immediately after clot placement using perfusion-
weighted MRI. These data support more robust preclinical assessment of complex, 
multimodal acute stroke therapies. 
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Figure Legends 
 
Fig. 1 Placement of an autologous clot in the middle cerebral artery (MCA) of the dog. (a) 
Digital Subtraction Angiography (DSA) prior to clot placement is shown. The arrows 
indicate the location of the MCA (b) Total MCA occlusion is shown in DSA post-clot 
placement. The dashed arrows depict the original course of the MCA, which is now 
absent.  (c) Time-of-flight (ToF) MRI shows an open internal carotid artery (ICA) and an 
occluded MCA. 
 
Fig. 2 Flowchart of image analysis. Apparent diffusion coefficient (ADC) and time-to-peak 
(TTP) maps were generated from diffusion-weighted imaging (DWI) and perfusion-
weighted imaging (PWI), respectively. ADC maps were used to calculate the final 
strokeinfarct volume. The entire brain in TTP maps was normalized with respect to a 
representative area on the contralateral side of the strokeinfarct region to generate 
relative TTP (rTTP) maps. rTTP maps were registered with ADC maps to count the voxels 
within the strokeinfarct volume. All voxels within the ADC-defined lesion were binned into 
one of four categories in the rTTP map. The total size of each bin, across the entire lesion 
volume, was used to predict the rate of strokeinfarct evolution. 
 
Fig. 3 Representative animal from the fast evolver group (Animal #4 from Table 1). (a) 
Final diffusion-weighted imaging (DWI) image showing the total extent of the infarct as a 
hyperintense region. (b) Apparent diffusion coefficient (ADC) map showing a hypointense 
region indicating the extent of infarct. The red line on the scale bar indicates the intensity 
level of the infarct region. (c) Post-mortem triphenyltetrazolium chloride (TTC) staining 
showing the final histological strokeinfarct size. Scale bar: 10 mm. (d) Relative time-to-
peak (rTTP) map derived from perfusion-weighted imaging (PWI) images. The color 
intensity of the infarct area voxels indicate an elevated intensity at or above the 20-s 
delay. Digital Subtraction Angiography (DSA) is shown in early (e) and delayed phase (f), 
which denote a lack of collaterals in the right hemisphere. The arrows indicate the location 
of the clot. 
 
Fig. 4 Representative animal from the slow evolver group (Animal #1 from Table 1). (a) 
Final diffusion-weighted imaging (DWI) image showing the total extent of the infarct as a 
hyperintense region. (b) Apparent diffusion coefficient (ADC) map showing a hypointense 
region indicating the extent of infarct. The red line on the scale bar indicates the intensity 
level of the infarct region. (c) Post-mortem triphenyltetrazolium chloride (TTC) staining 
showing the final histological strokeinfarct size. Scale bar: 10 mm. (d) Relative time-to-
peak (rTTP) map derived from perfusion-weighted imaging (PWI) images. The area of 
occlusion is seen only slightly elevated with a few voxels above the 20-s delay. Digital 
Subtraction Angiography (DSA) is shown in early (e) and delayed phase (f), which 
highlights the impact of the collaterals in the left hemisphere. The arrows indicate the 
location of the clot. 
 
Fig. 5 Quantification of fast and slow evolvers using diffusion-weighted imaging (DWI) 
apparent diffusion coefficient (ADC) maps and perfusion-weighted imaging (PWI) time-
to-peak (TTP) maps. (a) Ischemic core evolution as derived by ADC-thresholded maps 
and dichotomized to fast (orange) versus slow (blue) evolvers are shown. Based on lesion 
growth rate, animals were divided into fast (>50% total volume within 2 h) and slow (<50% 
total volume within 2 h) evolver groups. The plot shows the progression of slow and fast 
evolvers with the greatest difference occurring at about 2 h. Individual growth curves are 
shown for each animal in lighter shade. Error bars indicate SEM. (b) Correlation plot is 
shown indicating the agreement of infarct volumes between the final DWI image and the 
TTP map generated from the initial PWI images (R2 = 0.99). The dotted lines indicate 
95% confidence level. (c) Histogram binning from rTTP maps for fast and slow evolvers 
are shown. The voxels in the “slight delay” bin (4−8 s) of fast evolvers are significantly 
fewer compared to that of slow evolvers (**p < 0.0001). The dashed line near the left axis 
of the plot shows a cutoff at ~34%, which distinguishes between the fast and slow 
evolvers in the “slight delay” bin. The voxels in the “extended delay” bin (19+ s) of fast 
evolvers are significantly more compared to that of slow evolvers (*p = 0.0013). The 
dashed line near the right axis of the plot shows a cutoff at ~42%, which distinguish 
sdistinguishes between the fast and slow evolvers in the “extended delay” bin. The two 
middle bins of “moderate delay” (9−13 s) and “long delay” (14−18 s) did not show any 
significant differences between the slow and fast evolvers. Error bars indicate SEM.  
 
We thank the reviewers for their comments and have included the responses to their queries below in 
red. In addition, we rephrased terms like stroke volume and stroke rate with infarct volume and infarct 
evolution rate throughout the manuscript. We also updated the funding/conflict of interest information. 
 
Reviewer #1: In this study, the authors used DWI and PWI technology to divide ELVO dogs into fast 
evolvers and slow evolvers increasing the scientific rigor, which enabling more robust study design for 
follow-up interventional research. 
 
Some points need to be pay attention to: 
 
1.      In the figure 3 and figure 4, why were the infarcts located in the diferent side? Generally we select 
the same side of infarts in animal model for the rigor of the study. 
Thank you for pointing this out. The choice of left versus right side for infarct modeling was based on the 
angiographic features of the cervical ICA. We selected the larger ICA with sufficient non-tortuous origin 
for placement of the catheter. We revised our methods section to include this information as follows: 
"The side of clot injection was selected on the basis of the larger diameter and length of non-tortuous 
cervical ICA for delivery of this relatively large catheter." 
2.      The authors should add a scale to figure 3C and figure 4C. 
A scale has been added to the figures and the figure caption has been edited to include the scale 
information. We apologize for the oversight. 
3.      How is it defined in terms of distinguishing between slow and fast evolvers were ~34% for the 
"slight delay" and ~42% for the "extended delay" bins 
The definition was based on the spread of the data points in the fast and slow evolver categories in Fig 
5C for the “slight delay” and “extended delay” bins. ~34% and ~42% were approximately the halfway 
values between the boundary data points of the fast and slow evolvers. Hence, the rTTPIE (rTTP infarct 
evolution) index was used as the more quantitative measure to designate fast and slow evolvers. The 
Results section has been revised to now read as follows: “the respective cutoff marks to distinguish 
between slow and fast evolvers were ~34% for the “slight delay” and ~42% for the “extended delay” 
bins based on the minimal distance (halfway point) between the boundary points of each category. 
4.      The authors should give a calculation formula or specific method of rTTP and compare the affected 
area with the mirror image area. 
Thank you for the suggestion. As requested, we added this information to the revised methods section 
as follows: "To obtain a relative TTP (rTTP) map, TTP maps were normalized by subtracting the mean TTP 
derived from a contralateral region of interest (ROI; positioned in the periventricular area of the 
unaffected hemisphere in the mid-brain region) from the absolute TTP in each voxel using the following 
equation: 
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where n is the total number of voxels in the contralateral ROI. "  
 
5.      Why is there such a big difference in the selection of the age of the animals in the group, and the 
weight of the older animals in the aging state is very low, which may be an unstable factor in this study. 
The variability in animal age and weight relates to the different strains of dogs used in this study. 
However, size and age of the animal were not statistically different between the slow and fast evolver 
groups (see Table 2) assuaging concerns that these factors biased our results. Nevertheless, your point is 
well taken and we revised our limitation to briefly address this issue as follows: “There was a notable 
variation in animal age and weight related to the different strains of dogs included into our retrospective 
analysis. However, we did not find any significant age and weight difference between fast and slow 
evolvers, assuaging concerns of major confounding and may in fact indicate broad applicability of our 
results.” 
 
 
 
Reviewer #2: An excellent experimental model to hopefully get closer to answering the topical question 
of reasons for the gap between recanalized patients and those with good clinical outcome. The canine 
model is a close replica of the human circle of willis and hence can be a good experimental model to 
assess novel therapeutic targets in the future. Well designed study with MCA occlusion model. Good 
demonstration of the hypothesis of selecting out animals with slow progression of infarct volume vs fast 
progression. The utilization of MRI every 30 minutes to closely follow infarct evolution is a robust 
mechanism to study the phenomenon in question. This model can be applied to further prospective 
evaluation to validate further and then can be utilized to study interventions with novel therapeutic 
targets. 
We appreciate the enthusiasm of the reviewer and agree that this model will be applicable to 
prospective studies to validate therapeutic interventions. 
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Tables 
Table 1. Demographic data and infarct evolution rate of subjects 
Animal ID 
Age 
(months) 
Sex Weight (kg) 
Infarct 
evolution rate 
rTTPIEa index 
Animal 1 7.0 Female 21.2 Slow 0.003 
Animal 2 6.5 Male 14.7 Fast 2.615 
Animal 3 17.0 Male 8.9 Slow 0.125 
Animal 4 8.0 Female 21.3 Fast 5.043 
Animal 5 16.5 Male 9.3 Fast 2.676 
Animal 6 6.75 Female 22.8 Slow 0.074 
Animal 7 15.5 Male 13.0 Slow 0.882 
Animal 8 16.0 Male 12.5 Slow 0.099 
Animal 9 10.5 Female 23.9 Fast 2.634 
Animal 10 10.0 Female 23.4 Fast 1.721 
Animal 11 26.0 Male 8.2 Slow 0.286 
Animal 12 36.0 Female 10.1 Fast 1.908 
Animal 13 30.5 Female 9.8 Slow 0.767 
Animal 14 32.5 Female 9.4 Fast 3.896 
Mean ± SD 17.1 ± 10.2  14.9 ± 6.2  1.62 ± 1.59 
 
a rTTPIE – relative time-to-peak infarct evolution 
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 Table 2. Statistical summary of fast and slow evolvers 
 
 
 
 
               
a rTTPIE – relative time-to-peak infarct evolution 
 
 
 
Fast 
Evolvers 
Slow 
Evolvers 
p value 
Sex (% female) 71 43 0.32 
Age (months) 17.1 ± 12.1 17.0 ± 8.9 0.98 
Weight (kg) 16.0 ± 6.7 13.8 ± 5.9 0.52 
rTTPIEa index 2.93 ± 1.17 0.32 ± 0.36 0.0001 
